Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

Anti-CD 20 therapies have found significant uses in multiple sclerosis (MS). Based singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech, and Biogen) in neuroimmunological diseases, ocrelizumab (OCR; Ocrevus, Genentech) was developed as a treatment option for MS a...

Descripción completa

Detalles Bibliográficos
Autor principal: Avasarala, Jagannadha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661702/
https://www.ncbi.nlm.nih.gov/pubmed/29123374
http://dx.doi.org/10.1177/1177392817737515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661702/
https://www.ncbi.nlm.nih.gov/pubmed/29123374
http://dx.doi.org/10.1177/1177392817737515

Ejemplares similares